Catalent has entered an agreement to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.  The companies anticipate completing the transaction by the end of 2019, subject to regulatory approvals and customary closing conditions. 
 
The Anagni plant has served as one of the primary launch facilities for BMS’ new medicines. Upon closing, Catalent will continue to manufacture BMS’ current product portfolio at the site.  
 
Catalent will also bring potential new customers to the site for both biologics and oral solid dose manufacturing and packaging. In particular, this facility will provide Catalent biologics customers with access to an advanced sterile drug product fill/finish and packaging capacity in Europe to complement its existing sterile fill/finish capabilities in Belgium and its drug substance, analytical and fill/finish capabilities in North America. 
 
“We believe that the sale to Catalent will continue the vital role the Anagni facility plays for its workforce, the community and patients,” said Lou Schmukler, president, Global Product Development and Supply, Bristol-Myers Squibb. “This marks an important step in the ongoing evolution of our manufacturing network to support the company’s innovative product portfolio. Bristol-Myers Squibb has a long history in Italy, and we intend to maintain a continued strategic presence in Italy, which is critical for our ability to deliver transformational medicines to patients.”
 
Alessandro Maselli, Catalent’s president and chief operating officer, said, “The addition of the Anagni facility provides our European customers with great biologics and oral dose capabilities to accelerate their development programs and improve commercial supply.” He added, “Bristol-Myers Squibb has invested in the facility to create a center of excellence for new product launches with a robust quality and delivery record, and an employee base who shares Catalent’s operational excellence and patient focus.”